Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2733581
Reference Type
Journal Article
Subtype
Review
Title
Finasteride in the treatment of alopecia
Author(s)
Libecco, JF; Bergfeldt, WF
Year
2004
Is Peer Reviewed?
1
Journal
Expert Opinion on Pharmacotherapy
ISSN:
1465-6566
EISSN:
1744-7666
Volume
5
Issue
4
Page Numbers
933-940
Language
English
PMID
15102575
DOI
10.1517/14656566.5.4.933
Web of Science Id
WOS:000220703900018
Abstract
Finasteride is a 5alpha-reductase inhibitor approved for the treatment of male pattern hair loss. Originally approved for the treatment of benign prostatic hypertrophy in 1992, its approval was expanded in 1997 to include the treatment of androgenetic alopecia (AGA) in men at a dose of 1 mg/day. Finasteride inhibits 5alpha-reductase, thereby prohibiting the conversion of testosterone to dihydrotestosterone (DHT), which is implicated in the development of hairless in some men. Reduction in DHT results in a significant improvement in subjective and objective assessments of hair growth and density. Finasteride is well-tolerated with a favourable adverse event history. The most common adverse events include reduced libido, decreased ejaculate volume and gynaecomastia.
Keywords
5 alpha-reductase inhibitor; administration; alopecia; androgenetic alopecia; dosage; finasteride; hair loss; male pattern baldness; pharmacodynamics; pharmacokinetics; tolerability
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity